Research Compound Blend
$165.00
Research identity: 60-count small-molecule blend. The bottle label states BAM15 50 mg plus SLU-PP-332 250 mcg.
Catalog scope: The listed strengths reproduce the bottle statement without making a per-unit claim and are not a dose, schedule, or use instruction. These are small molecules, not peptides. For laboratory research only; not for human or veterinary use.
BUILD ONE COMPLETE LIST
Add this item, keep browsing, and add every product or option you need. Your list stays saved in this browser until you send one complete email request or remove it.
RESEARCH HERE · COMPOUND DOSSIER
Plain-language identity, mechanism, evidence maturity, study endpoints, limitations, and direct source records—organized for careful reading, never copied from a dosing site.
TWO SMALL-MOLECULE RESEARCH AGENTS
A 60-count catalog blend whose label states BAM15 50 mg plus SLU-PP-332 250 mcg. These are two chemically distinct small molecules—not peptides—with separate preclinical evidence records and no controlled human evidence for the combined product.
01
BAM15 is studied as a mitochondrial protonophore uncoupler. SLU-PP-332 is studied as an agonist of estrogen-related receptors. The two mechanisms are different, and evidence for either component does not become evidence for the commercial blend.
02
03
EVIDENCE SNAPSHOT
These papers test specific research materials in defined cell or mouse models. None tests this 60-count blend, and none establishes a consumer use.
Preclinical study of mitochondrial uncoupling, energy balance, and metabolic endpoints in mice.
PMID 32409697 ↗ 2022 · MOUSE STUDYBAM15 in sarcopenic-obesity modelsAnimal study examining body-composition, muscle, and metabolic measurements.
PMID 35304976 ↗ 2023 · CELL & MOUSE STUDYSLU-PP-332 and exercise-mimetic signalingFoundational ERR-agonist record with cellular signaling and mouse endurance endpoints.
PMID 36988910 ↗DETAILED COMPOUND GUIDE
Popular pages often compress mechanism, mouse findings, and promotional conclusions into one story. This guide keeps the components, models, and evidence limits separate.
In mouse studies, BAM15-mediated mitochondrial uncoupling was associated with changes in energy expenditure, adiposity, insulin sensitivity, liver-related measurements, and—in a separate sarcopenic-obesity model—muscle and body-composition endpoints.
SLU-PP-332 activated ERR-linked transcriptional programs in experimental systems. The foundational paper reported increased oxidative-muscle fibers and endurance-related measurements in mice; another mouse study examined metabolic-syndrome endpoints.
Scope: these are preclinical component findings. They do not establish a result for this blend or a person.
Neither molecule is a peptide. Calling the blend a peptide product would be a chemistry error.
No controlled human trial of BAM15, SLU-PP-332, or this exact combination was located in the indexed record used for this dossier. Mouse endurance, weight, liver, or glucose endpoints cannot be converted into a human benefit statement.
A later paper on the related compound SLU-PP-915 describes SLU-PP-332 as lacking oral bioavailability. That statement is especially relevant to a marketed tablet or capsule, but it does not independently test this bottle.
There is no FDA-approved prescribing label or validated human contraindication and interaction list for either research agent. Mitochondrial uncoupling is a mechanism requiring particular caution because excessive uncoupling can be hazardous; a favorable result in a mouse experiment is not a safety clearance.
No controlled study was found evaluating BAM15 and SLU-PP-332 together, with medications, or in pregnancy, organ disease, cardiovascular disease, or other clinical contexts.
The catalog statement preserves the bottle wording without converting it into a per-unit claim. The physical label and lot record should establish whether each strength is per unit, per serving, or per bottle, along with identity and quantity evidence for both compounds.
A meaningful quality record should address both identities, content uniformity across the 60-count lot, assay, degradants or contaminants, and stability. A single aggregate purity number may not answer the component ratio.
SUPPORTED PRECLINICALLYComponent mechanisms and selected cellular or mouse metabolic endpoints
MECHANISTIC CONTEXTMitochondrial uncoupling plus ERR agonism
NOT ESTABLISHEDHuman fat loss, endurance, muscle, liver, glucose, longevity, or wellness outcomes
NOT VALIDATEDExact blend performance, oral exposure, human protocols, or commercial stacking plans
RESEARCH PROTOCOL MAP
This is a non-prescriptive design and documentation checklist. It does not supply a human dose, route, schedule, preparation method, or administration instruction.
Record dosage form, lot, manufacturer wording, and whether 50 mg and 250 mcg refer to each unit, a serving, or the entire bottle. Do not fill that gap with an assumption.
Use fit-for-purpose identity and quantitative methods for BAM15 and SLU-PP-332 separately, with content-uniformity and stability questions defined before testing.
Define the model, vehicle, component controls, blend condition, prespecified primary endpoint, exposure documentation, and interpretation limits in the approved laboratory plan.
Document model-specific stopping criteria and quality failures. Cell and mouse findings remain preclinical and do not become human-use instructions.
REFERENCE DESK
The SLU-PP-332 guide claims were cross-checked against primary papers. BAM15 conclusions come from its separate primary record; no exact commercial-blend study was found.
BENEFITS CLAIM INDEX
CELL / RODENTChanges in respiration, energy expenditure, endurance, body composition, and selected metabolic markers in experimental models
PRECLINICAL ONLYFatty-liver, muscle, cardiovascular, or metabolic-disease applications studied in animals
NOT ESTABLISHED IN HUMANSFat loss, exercise replacement, muscle growth, glucose control, heart protection, anti-aging, or improved performance
COMPONENT IDENTITY
SIDE-EFFECT & INTERACTION INDEX
Commercial pages list broad cautions, but controlled human safety, interaction, and adverse-event rates are not established for these agents or the blend.
Unknown does not mean safe. Mechanism, model dose, exposure route, formulation, impurities, and species all affect translation.
STORAGE & HANDLING
No. Both are small molecules. Their chemical structures and evidence records differ from peptide materials.
No controlled human study of this exact 60-count blend was found in the record used here.
No. A related-compound paper specifically describes SLU-PP-332 as lacking oral bioavailability, and no paper cited here tests this bottle.
Whether each strength is stated per unit, serving, or bottle; the exact dosage form; lot; and batch-specific identity and quantity evidence for both components.
Confirm what “50 mg + 250 mcg” modifies on the physical label before publishing a per-tablet or per-capsule statement.
Identity, assay, and content uniformity should be demonstrated for both components; one purity number may not answer the ratio.
Preclinical metabolic or endurance endpoints cannot establish a clinical benefit, safe amount, or oral performance for this bottle.